Immune Response to RBC Antigens
对红细胞抗原的免疫反应
基本信息
- 批准号:10733353
- 负责人:
- 金额:$ 72.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdenosineAdverse eventAffectAgeAge of OnsetAgingAnemiaAntigensAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmune hemolytic anemiaAutoimmunityAutomobile DrivingBindingBiological FactorsBiological TestingBlood PlateletsBlood donorCD4 Positive T LymphocytesCellsClinicalComplicationDataDevelopmentEmigrantErythrocyte TransfusionErythrocytesEtiologyEventFailureFatigueFemaleFlow CytometryFrequenciesFunctional disorderFutureHematologyHemoglobinuriaHemolysisHemolysis InductionHospitalizationHumanImmuneImmune ToleranceImmune checkpoint inhibitorImmune responseImmune systemImmunotherapyIndividualInflammatoryInterleukin-10KnowledgeLifeMalignant NeoplasmsMediatingMedicalModelingMorbidity - disease rateMusPallorPathogenesisPathway interactionsPatientsPlatelet GlycoproteinsPopulationPre-Clinical ModelPreventionProductionPublishingRegulatory T-LymphocyteRelapseReportingResearchReticulocytosisRiskRoleSamplingSignal PathwaySignal TransductionSignaling MoleculeSplenomegalySupportive careSystemic Lupus ErythematosusT-LymphocyteT-Lymphocyte SubsetsTestingThrombocytopenic PurpuraThymus GlandTimeTissuesautoreactive T cellautoreactivitycancer immunotherapycancer therapycheckpoint therapyclinically significantcytokineds-DNAexperienceextracellularhuman diseaseimmune checkpointinnovationinsightmalemortalitymouse modelnovelnovel therapeutic interventionpre-clinicalpreventsexsuccesstissue oxygenationtranscriptome sequencingtranscriptomicstreatment strategyvirtual
项目摘要
ABSTRACT
Autoimmune hemolytic anemia (AIHA) causes significant morbidity and mortality; however, we still do not fully
understand how immune tolerance to red blood cells (RBCs) is established or broken. Given that RBCs are
required for life, are abundant, and have essential functions (e.g., tissue oxygenation), one would predict
stringent immune tolerance; however, tolerance failure occurs frequently. Indeed, 0.1% of healthy blood donors
and ~8% of hospitalized patients have detectable RBC autoantibodies. These autoantibodies can be clinically
significant, by inducing RBC clearance, hemolysis, antigen modulation, and increased risk for future AIHA or
cancer. Patients with AIHA present with pallor, fatigue, hemoglobinuria, splenomegaly, and/or life-threatening
hemolysis. Treatment strategies have variable success, with high relapse rates and mortality in ~11% of cases.
Supportive care using RBC transfusions is challenging as most autoantibodies recognize ubiquitous RBC
antigens; thus, virtually all donor units are crossmatch incompatible. The etiology of AIHA is generally unknown
and up to 50% of AIHA cases have no identifiable cause (“primary”). Secondary AIHA is frequently associated
with other autoimmune diseases and has been recently observed as a complication of checkpoint inhibitor
immunotherapies in the treatment of cancer. Thus, loss of tolerance to RBC autoantigens is an important medical
and scientific problem. To elucidate RBC tolerance mechanisms, we developed an innovative primary AIHA
murine model, which closely reflects human disease, a subset of mice develops age-onset hemolytic RBC
autoantibodies, anemia, splenomegaly, and reticulocytosis. Using this model, we pinpointed a 3-week
developmental timeframe during which RBC autoreactive recent thymic emigrants encounter RBC antigens and
become tolerized. Transcriptomic analysis identified novel pathways whose activity correlates with autoreactive
T cell tolerization, including 1) checkpoint molecules, 2) IL-10, and 3) purinergic signaling. Because AIHA is the
most frequently reported hematological adverse event due to cancer immunotherapy, we developed a novel
secondary AIHA model with checkpoint inhibitors. Loss of tolerance in the primary and secondary AIHA mouse
models is associated with an imbalance between regulatory T cells (Tregs) and proinflammatory TH17 T cells,
as well as a distinct population of CD39+ T cells. Herein, we leverage our preclinical AIHA mouse models to
determine which signaling molecules and/or pathways (i.e., checkpoint molecules, IL-10, or purinergic signaling
molecules) are required for T cell tolerance and AIHA prevention, and elucidate how biological factors, such as sex
and age, affect these requirements. The function of unique T cell populations (i.e., recent thymic emigrants, Treg
subsets, and CD39+ T cells) will also be defined. Understanding how the immune system responds to RBC
antigens will provide insight into not only autoimmunity to RBCs but may also have applicability to other
autoantigens present at high concentrations (e.g., platelet autoantigens, dsDNA) thereby making this a powerful
platform to study the requirements for tolerance to self-antigens in general.
摘要
自身免疫性溶血性贫血(AIHA)导致显著的发病率和死亡率;然而,我们仍然没有完全了解
了解如何建立或破坏对红细胞(RBC)的免疫耐受。因为RBC是
生命所需的,丰富的,并具有基本功能(例如,组织氧合),人们会预测
严格的免疫耐受;然而,耐受失败经常发生。0.1%的健康献血者
约8%的住院患者可检测到RBC自身抗体。这些自身抗体可以在临床上
通过诱导RBC清除、溶血、抗原调节和增加未来AIHA的风险,
癌AIHA患者表现为苍白、疲乏、血红蛋白尿、脾肿大和/或危及生命
溶血治疗策略的成功率各不相同,约11%的病例复发率和死亡率较高。
使用RBC输注的支持性护理具有挑战性,因为大多数自身抗体识别普遍存在的RBC
抗原;因此,实际上所有供体单位都是交叉配型不相容的。AIHA的病因通常是未知的
高达50%的AIHA病例没有可识别的原因("原发性")。继发性AIHA通常与
与其他自身免疫性疾病,最近已被观察到作为检查点抑制剂的并发症
免疫疗法治疗癌症。因此,对RBC自身抗原的耐受性丧失是一个重要的医学问题。
和科学问题。为了阐明RBC耐受机制,我们开发了一种创新的原发性AIHA,
一种密切反映人类疾病的鼠模型,一部分小鼠出现年龄发作性溶血性RBC
自身抗体、贫血、脾肿大和网织红细胞增多症。利用这个模型,我们确定了一个为期3周的
红细胞自身反应性近期胸腺移行细胞遇到红细胞抗原的发育时间表,
变得宽容。转录组学分析鉴定了其活性与自身反应相关的新途径。
T细胞耐受化,包括1)检查点分子,2)IL-10,和3)嘌呤能信号传导。因为AIHA是
由于癌症免疫治疗最常报告的血液学不良事件,我们开发了一种新的
检查点抑制剂的继发性AIHA模型。原发性和继发性AIHA小鼠的耐受性丧失
模型与调节性T细胞(TCLs)和促炎性TH17 T细胞之间的不平衡有关,
以及CD39 + T细胞的独特群体。在此,我们利用我们的临床前AIHA小鼠模型,
确定哪些信号分子和/或途径(即,检查点分子、IL-10或嘌呤能信号传导
分子)是T细胞耐受性和AIHA预防所必需的,并阐明了生物因素,如性别,
和年龄,影响这些要求。独特的T细胞群体的功能(即,近期胸腺移出者,Treg
亚群和CD39 + T细胞)。了解免疫系统如何响应RBC
抗原将不仅提供对RBC的自身免疫的了解,而且还可以适用于其他免疫系统。
以高浓度存在的自身抗原(例如,血小板自身抗原,dsDNA),从而使其成为一种强大的
该平台用于研究一般对自身抗原耐受性的要求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Krystalyn E Hudson其他文献
Iron Overload and Iron-Induced Microbiome Changes May Affect Lymphoid Levels Post Bone Marrow Transplant and Graft-Versus-Host Disease Survival in Mice
- DOI:
10.1182/blood-2022-167300 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Annie Qiu;Lin Wang;Flavia Dei Zotti;Krystalyn E Hudson;Eldad A. Hod;Francesca La Carpia - 通讯作者:
Francesca La Carpia
Antibody-Mediated Antigen Loss Can Switch an Augmented Immune Response to Antibody-Mediated Immunosuppression
- DOI:
10.1182/blood-2022-170081 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Ryan Philip Jajosky;Jerry W. Allen;Patricia E Zerra;Cheryl L Maier;Satheesh Chonat;Chance John Luckey;John D. Roback;Ross M. Fasano;Cassandra D. Josephson;John P Manis;Li Chai;Jeanne E. Hendrickson;Krystalyn E Hudson;Connie M. Arthur;Sean R. Stowell - 通讯作者:
Sean R. Stowell
Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels
- DOI:
10.1182/blood-2022-169746 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Tiffany Thomas;Annie Qiu;Christopher Y Kim;Dominique E Gordy;Anabel Miller;Maria Tredicine;Elizabeth Stone;Monika Dzieciatkowska;Eldad A. Hod;Angelo D'Alessandro;Steven L Spitalnik;James C Zimring;Imo J Akpan;Chance John Luckey;Krystalyn E Hudson - 通讯作者:
Krystalyn E Hudson
Development and consequences of red blood cell autoantibodies: warm autoimmune hemolytic anemia
- DOI:
10.1016/j.coi.2025.102604 - 发表时间:
2025-08-01 - 期刊:
- 影响因子:5.800
- 作者:
Flavia Dei Zotti;Krystalyn E Hudson - 通讯作者:
Krystalyn E Hudson
Krystalyn E Hudson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Krystalyn E Hudson', 18)}}的其他基金
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 3
红细胞输注同种免疫的基本和转化机制。
- 批准号:
10711670 - 财政年份:2023
- 资助金额:
$ 72.46万 - 项目类别:
Regulation of RBC Alloimmunization by Naturally Occurring and Adaptive Antibodies
天然存在和适应性抗体对红细胞同种免疫的调节
- 批准号:
9893151 - 财政年份:2019
- 资助金额:
$ 72.46万 - 项目类别:
Regulation of RBC Alloimmunization by Naturally Occurring and Adaptive Antibodies
天然存在和适应性抗体对红细胞同种免疫的调节
- 批准号:
10160944 - 财政年份:2019
- 资助金额:
$ 72.46万 - 项目类别:
Regulation of RBC Alloimmunization by Naturally Occurring and Adaptive Antibodies
天然存在和适应性抗体对红细胞同种免疫的调节
- 批准号:
9381275 - 财政年份:2017
- 资助金额:
$ 72.46万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 72.46万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 72.46万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 72.46万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 72.46万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 72.46万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 72.46万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 72.46万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 72.46万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 72.46万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 72.46万 - 项目类别: